Celldex Therapeutics, Inc. (CLDX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $41.70. The rating moved from Overbought to Neutral on August 15, 2026.

• Public ratingNeutral (as of August 19, 2026)
• Last close$41.70
• Last changeMoved from Overbought to Neutral on August 15, 2026
• SectorHealthcare
• IndustryBiotechnology

AI analysis

Celldex Therapeutics, Inc. (CLDX) is a clinical-stage biopharma with value concentrated in its pipeline and upcoming clinical milestones. Sector tailwinds for biologics and elevated M&A multiples increase the likelihood of partnership or acquisition interest, while the company’s limited commercial revenue keeps near-term operational execution relatively simple. Key upside catalysts are clinical readouts and licensing discussions; downside stems from binary clinical outcomes, financing needs, and payer/regulatory headwinds. With market risk appetite currently balanced and no major macro shocks in the immediate window, the stock’s near-term path will largely track trial newsflow and any partnership announcements.

Key factors

• Pipeline-driven upside: clinical-stage assets with near-term readouts that could meaningfully re-rate valuation if positive
• Sector thematic tailwinds for biologics and CRO/CDMO demand support partner interest and potential licensing/M&A optionality
• M&A environment: recent elevated biotech acquisition multiples provide a favorable backdrop for strategic acquisition or premium partnerships
• Stable near-term market backdrop: balanced risk appetite in the market reduces likelihood of disorderly intraday moves around data releases
• Manageable commercial exposure: limited dependence on large-scale commercial launch execution reduces near-term revenue execution risk but limits current revenue

Risks

• Clinical trial failure or disappointing readouts that could cause sharp share-price declines
• Cash burn and financing risk if upcoming milestones require capital raising under weak market conditions
• Competitive landscape in oncology/biologics with larger pharma companies and other emerging therapies
• Regulatory delays or safety concerns that extend timelines or increase development costs
• Payer pricing pressure and ongoing MA/payer rationalization that could complicate future commercialization economics
• Limited social/research sentiment data and thin near-term liquidity can amplify volatility around news

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.